Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Genaera Corporation has announced that the investigational new drug application submitted to the FDA for trodusquemine in type 2 diabetes is now in effect.
Subscribe to our email newsletter
This investigational new drug (IND) application represents the second IND filed by the company in 2007 for MSI- 1436 (trodusquemine). MSI-1436 is a novel therapeutic acts by regulating insulin and leptin receptor signaling through inhibition of the tyrosine phosphatase, PTP-1B.
Jack Armstrong, president and CEO of Genaera, said: “Since MSI-1436 has demonstrated significant potential to impact both the insulin and leptin pathways, we believe this new IND provides us with the opportunity for additional indications and a much broader potential market. Therefore, we are implementing a clinical plan which evaluates the drug’s potential in type 2 diabetes, in addition to our ongoing obesity studies.”